Disease · EFO_1002029
chronic rhinosinusitis with nasal polyps
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. chronic rhinosinusitis with nasal polyps. Diseases, record EFO_1002029. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1002029
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- chronic rhinosinusitis with nasal polyps
- Open Targets ID
- EFO_1002029
- Other names
- CRSwNP
- Highest stage of its drugs
- Phase 3, for 11 of its 22 drugs, from ClinicalTrials.gov and TTD
Source Open Targets
Drugs22
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DUPILUMAB | CHEMBL2108675 | Antibody | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| MEPOLIZUMAB | CHEMBL2108429 | Antibody | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| BENRALIZUMAB | CHEMBL1742991 | Antibody | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| ITEPEKIMAB | CHEMBL4594594 | Antibody | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| OMALIZUMAB | CHEMBL1201589 | Antibody | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| STAPOKIBART | CHEMBL5095324 | Antibody | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| DEPEMOKIMAB | CHEMBL4650469 | Antibody | Phase 3 | ClinicalTrials.gov and TTD | 4 | 3 | 3 | Drugs and targets |
| DOXYCYCLINE | CHEMBL1200699 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| MOMETASONE FUROATE | CHEMBL1161 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| TEZEPELUMAB | CHEMBL3707229 | Antibody | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 22
See all 22 drugsTargets36
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 3 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| IL5 | Interleukin-5 | 2 | Interleukin-5 inhibitor | Phase 3 | https://conductscience.org/library/genes/3567 | Drugs and targets |
| CACNA1C | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 1 | https://conductscience.org/library/genes/775 | Drugs and targets |
| CACNA1D | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 1 | https://conductscience.org/library/genes/776 | Drugs and targets |
| CACNA1F | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 1 | https://conductscience.org/library/genes/778 | Drugs and targets |
| CACNA1S | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 1 | https://conductscience.org/library/genes/779 | Drugs and targets |
| CYSLTR1 | Cysteinyl leukotriene receptor 1 | 1 | Cysteinyl leukotriene receptor 1 antagonist | Phase 1/2 | https://conductscience.org/library/genes/10800 | Drugs and targets |
| IGHE | Immunoglobulin heavy constant epsilon | 1 | Ig epsilon chain C region inhibitor | Phase 3 | https://conductscience.org/library/genes/3497 | Drugs and targets |
| IL13 | Interleukin-13 | 1 | Interleukin-13 inhibitor | Phase 3 | https://conductscience.org/library/genes/3596 | Drugs and targets |
| IL33 | Interleukin-33 | 1 | Interleukin-33 inhibitor | Phase 3 | https://conductscience.org/library/genes/90865 | Drugs and targets |
1 to 10 of 36
See all 36 targetsTrials49
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03085797 | Effect of Mepolizumab in Severe Bilateral Nasal Polyps | Phase 3 | 414 | 2020-12-17 | Nasal Polyps | MEPOLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04718103 | A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype | Phase 3 | 397 | 2024-11-29 | Asthma | DEPEMOKIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02291549 | S8 Sinus Implant in Chronic Sinusitis Patients With Recurrent Nasal Polyps | Phase 3 | 300 | 2018-07-09 | Chronic Sinusitis, Nasal Polyposis | MOMETASONE FUROATE | Its record names the disease | ClinicalTrials.gov |
| NCT04157335 | Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID) | Phase 3 | 295 | 2026-02-19 | Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis | BENRALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02912468 | A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps | Phase 3 | 276 | 2019-07-25 | Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) | DUPILUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05274750 | Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | 276 | 2025-12-03 | Nasal Polyps | DEPEMOKIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05281523 | Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2) | Phase 3 | 264 | 2025-09-09 | Nasal Polyps | DEPEMOKIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03478930 | An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | 249 | 2021-05-11 | Nasal Polyps, Chronic Rhinosinusitis | OMALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04607005 | Efficacy and Safety of Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)/ Eosinophilic Chronic Rhinosinusitis (ECRS) | Phase 3 | 169 | 2024-11-25 | Nasal Polyps | MEPOLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03280550 | A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | 138 | 2020-03-23 | Nasal Polyps, Chronic Rhinosinusitis | OMALIZUMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 49
See all 49 trialsComparisons in its trials42
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| GSK3511294 vs Placebo: deaths from any cause | 0 of 251 | 0 of 129 | 380 | NCT04718103 | Trial comparisons |
| GSK3511294 vs Placebo: serious adverse events | 19 of 251 | 13 of 129 | 380 | NCT04718103 | Trial comparisons |
| Treatment vs Control: deaths from any cause | 0 of 201 | 0 of 99 | 300 | NCT02291549 | Trial comparisons |
| Treatment vs Control: serious adverse events | 1 of 201 | 0 of 99 | 300 | NCT02291549 | Trial comparisons |
| Dupilumab 300 mg vs Placebo: deaths from any cause | 0 of 143 | 0 of 132 | 275 | NCT02912468 | Trial comparisons |
| Dupilumab 300 mg vs Placebo: serious adverse events | 6 of 143 | 19 of 132 | 275 | NCT02912468 | Trial comparisons |
| Double Blind Benralizumab vs Double Blind Placebo: Percentage of Participants With Surgery and/or Use SCS for CRSwNP | 26 of 139 | 30 of 135 | 274 | NCT04157335 | Trial comparisons |
| Double Blind Benralizumab vs Double Blind Placebo: Percentage of Participants With Surgery for CRSwNP | 8 of 139 | 10 of 135 | 274 | NCT04157335 | Trial comparisons |
| Double Blind Benralizumab vs Double Blind Placebo: Percentage of Participants With SCS Use for CRSwNP | 21 of 139 | 22 of 135 | 274 | NCT04157335 | Trial comparisons |
| Depemokimab vs Placebo: deaths from any cause | 0 of 143 | 0 of 128 | 271 | NCT05274750 | Trial comparisons |
1 to 10 of 42
See all 42 comparisons in its trialsPapers from its trials43
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 38749694 | RESULT | 1 | PubMed |
| 42956801 | DERIVED | 1 | PubMed |
| 42496183 | DERIVED | 1 | PubMed |
| 41868651 | DERIVED | 1 | PubMed |
| 41461999 | DERIVED | 3 | PubMed |
| 41022848 | DERIVED | 1 | PubMed |
| 40824573 | DERIVED | 1 | PubMed |
| 40037388 | DERIVED | 2 | PubMed |
| 39618256 | DERIVED | 1 | PubMed |
| 39393433 | DERIVED | 1 | PubMed |
1 to 10 of 43
See all 43 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_1002029
GET https://conductscience.org/api/diseases/v1/EFO_1002029/drugs?page=2